Adjunct Professor
Department of Biostatistics
University of Nebraska Medical Center
College of Public Health
Professional Summary
- 2023-Present, Adjunct Professor, UNMC College of Public Health
- 2015-2023, Distinguished Scientist, Merck and Co.
- 2014-2015, Visiting Professor, Department of Biostatistics & Medical Informatics, University of Wisconsin-Madison
- 2007-2014, Professor, Department of Biostatistics, College of Public Health, University of Nebraska Medical Center
- 1989-2007, Professor and Chairman, Department of Preventative and Societal Medicine, College of Medicine, University of Nebraska Medical Center
- 1986-1989, Associate Professor, Department of Biostatistics, Harvard School of Public Health
- 1981-1986, Assistant Professor, Department of Biostatistics, Harvard School of Public Health
- 1980-1981, Lecturer, Department of Biostatistics, Harvard School of Public Health
- 1979-1980, Assistant Professor, Department of Community & Family Medicine, University of Southern California
- 1977-1979, Instructor, Department of Community & Family Medicine, University of Southern California
Education
- PhD Biostatistics, University of Washington, 1979
- BA Mathematics, SUNY Buffalo, 1973
Research interests
- My research interests include the design, conduct and analysis of clinical trials, especially cancer clinical trials, time.-to-event analyses and medical ethics
Selected Publications
- Anderson JR, Bernstein L, Pike MC. Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis. Biometrics. 38(2): 407-16. 1982.
- Anderson JR, Wilson JF, Jenkin DT, Meadows AT, Kersey J, Chilcote RR, Coccia P, Exelby P, Kushner J, Siegel S, Hammond D. Childhood non-Hodgkin’s lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2- L2). The New England Journal of Medicine. 308(10): 559-65. 1983.
- Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1(11): 710-9. 1983.
- Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. The New England Journal of Medicine. 327(21): 1478-84. 1992.
- Anderson JR, Jameton A, Reitemeier PJ, Prentice E. The case of two devices: disclosure to subjects following Phase IV (post-marketing) research. IRB. 17(3): 6-9. 1996.
- Raney RB, Maurer HM, Anderson JR, Andrassy RJ, Donaldson SS, Qualman SJ, Wharam MD, Wiener ES, Crist WM. The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols. Sarcoma. 5(1): 9-15. 2001.
- Anderson JR, Schonfeld TL, Kelso TK, Prentice ED. Women in early phase trials: an IRB’s deliberations. IRB. 25(4): 7-11. 2003.
- Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 26(24): 3913-5. 2008.
- Anderson JR, High R. Alternatives to the standard Fleming, Harrington, and OBrien futility boundary. Clinical Trials (London, England). 8(3): 270-6. 2011.
- Spunt SL, Million L, Chi YY, Anderson J, Tian J, Hibbitts E, Coffin C, McCarville MB, Randall RL, Parham DM, Black JO, Kao SC, Hayes-Jordan A, Wolden S, Laurie F, Speights R, Kawashima E, Skapek SX, Meyer W, Pappo AS, Hawkins DS. A Risk-based Treatment Strategy for Non-rhabdomyosarcoma Soft-tissue Sarcomas in Patients Younger than 30 years (ARST0332): A Children's Oncology Group Prospective Study. Lancet Oncol. 2020 Jan;21(1):145-161.
- Robert C, Carlino MS, McNeil C, Ribas A, Grob JJ, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance A, Daud AI, Hamid O, Larkin J, Anderson J, Krepler C, Grebennik D, Long GV. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. J Clin Oncol. 2023 Aug 20;41(24):3998-4003.